Table 1.

Baseline Characteristics of the 48 Study Patients

Patients Per Dose Level and Age Group≤2 Years>2 Years
 250 mg/m2   3 7*
 300 mg/m2   2 9
 350 mg/m2   013
 400 mg/m2   0 14
Median age in years (range)  7.7  (0.53–14.4)
Sex (M/F)28/20
Route of acquisition of HIV infection
  Vertical 40
  Blood products  8
Race/ethnicity
  African-American 19
  Hispanic  6
  Caucasian 21
  Other  2
Median length of previous therapy in years (n = 45; range)  4.4  (0–8.6)
  Treatment with didanosine (n = 40) in years (range)  1.4  (0–5.5)
  Treatment with zidovudine (n = 45) in years (range)  2.3  (0–8.6)
Median CD4 cell count/mm3(range)105  (0–2022)
Median CD4 cell percentage (range)  8  (0–37)
Median log10 HIV RNA copies/mL plasma (range)  5.16  (2.96–6.25)
  • * Two patients received prior treatment with KNI-272.

  • One patient received prior treatment with KNI-272.